Abstract
The secosteroid hormone 1,25-dihydroxyvitamin D3 (1,25-(OH)2D3) is a key player in the regulation of bone mineralization and calcium homeostasis. In addition, 1,25-(OH)2D3 has antiproliferative and prodifferentiation effects on various cells in vitro and in vivo. The growthinhibitory properties of 1,25-(OH) 2D3 could be harnessed in the treatment of cancer. However, its use as an anti-cancer drug is limited because of the calcemic effects of pharmacological doses. In an attempt to dissociate the antiproliferative and calcemic effects, numerous vitamin D3 analogs were developed. The mechanisms by which 1,25-(OH)2D3 and 1,25-(OH)2D3 analogs exert their growth-inhibitory effects are not clear but include effects on cell differentiation, apoptosis, cell cycle regulation, metastases, and angiogenesis. In the current review aspects involved in the tumor suppressive activity of 1,25-(O H) 2D3 a nd 1,25-(O H) 2D3 a na logs will be a ddre sse d. The use of vita min D3 compounds, a lone or in combination with other drugs, in cancer treatment and the potential draw backs will also be discussed.
Current Drug Targets
Title: Vitamin D and Vitamin D Analogs in Cancer Treatment
Volume: 3 Issue: 1
Author(s): G.J.C.M. van den Bemd and G.T.G. Chang
Affiliation:
Abstract: The secosteroid hormone 1,25-dihydroxyvitamin D3 (1,25-(OH)2D3) is a key player in the regulation of bone mineralization and calcium homeostasis. In addition, 1,25-(OH)2D3 has antiproliferative and prodifferentiation effects on various cells in vitro and in vivo. The growthinhibitory properties of 1,25-(OH) 2D3 could be harnessed in the treatment of cancer. However, its use as an anti-cancer drug is limited because of the calcemic effects of pharmacological doses. In an attempt to dissociate the antiproliferative and calcemic effects, numerous vitamin D3 analogs were developed. The mechanisms by which 1,25-(OH)2D3 and 1,25-(OH)2D3 analogs exert their growth-inhibitory effects are not clear but include effects on cell differentiation, apoptosis, cell cycle regulation, metastases, and angiogenesis. In the current review aspects involved in the tumor suppressive activity of 1,25-(O H) 2D3 a nd 1,25-(O H) 2D3 a na logs will be a ddre sse d. The use of vita min D3 compounds, a lone or in combination with other drugs, in cancer treatment and the potential draw backs will also be discussed.
Export Options
About this article
Cite this article as:
G.J.C.M. van den Bemd and G.T.G. Chang , Vitamin D and Vitamin D Analogs in Cancer Treatment, Current Drug Targets 2002; 3 (1) . https://dx.doi.org/10.2174/1389450023348064
DOI https://dx.doi.org/10.2174/1389450023348064 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Doxycycline in Mitochondrial Mediated Pathway of Apoptosis: A Systematic Review
Anti-Cancer Agents in Medicinal Chemistry The Role of Clusterin in Carcinogenesis and its Potential Utility as Therapeutic Target
Current Medicinal Chemistry Targeting Clusterin Induces Apoptosis, Reduces Growth Ability and Invasion and Mediates Sensitivity to Chemotherapy in Human Osteosarcoma Cells
Current Pharmaceutical Biotechnology Discovery of Small Molecule c-Met Inhibitors: Evolution and Profiles of Clinical Candidates
Anti-Cancer Agents in Medicinal Chemistry The Parathyroid Hormone Receptorsome and the Potential for Therapeutic Intervention
Current Drug Targets Gene Therapy Approaches for the Selective Killing of Cancer Cells
Current Pharmaceutical Design Potentiation of Anti-Cancer Treatment by Modulators of Energy Metabolism
Current Pharmaceutical Biotechnology Berberine Exerts Anti-cancer Activity by Modulating Adenosine Monophosphate- Activated Protein Kinase (AMPK) and the Phosphatidylinositol 3-Kinase/ Protein Kinase B (PI3K/AKT) Signaling Pathways
Current Pharmaceutical Design Tubulin-Targeting Agents in Hybrid Drugs
Current Medicinal Chemistry Biosystems Engineering of Prokaryotes with Tumor-Killing Capacities
Current Pharmaceutical Design Hypoxia-Inducible Factor-1 (HIF-1): A Potential Target for Intervention in Ocular Neovascular Diseases
Current Drug Targets LHON: Mitochondrial Mutations and More
Current Genomics Targeting Key Transporters in Tumor Glycolysis as a Novel Anticancer Strategy
Current Topics in Medicinal Chemistry TRYCAT Pathways Link Peripheral Inflammation, Nicotine, Somatization and Depression in the Etiology and Course of Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Potential Role for High and Low Molecular Weight Tissue Transglutaminases in Transforming Mammalian Cell Properties
Current Drug Targets - Immune, Endocrine & Metabolic Disorders The Safety and Efficacy of Parathyroid Hormone (PTH) as a Biological Response Modifier for the Enhancement of Bone Regeneration
Current Drug Safety Kinase Phosphorylation-based Mechanisms of PARP Inhibitor Resistance During Synthetic Lethal Oncotherapy
Current Signal Transduction Therapy Hypoxic Regulation of Metastasis via Hypoxia-Inducible Factors
Current Molecular Medicine The Role of YY1 in Oncogenesis and Its Potential as a Drug Target in Cancer Therapies
Current Cancer Drug Targets High-Content Analysis of Kinase Activity in Cells
Combinatorial Chemistry & High Throughput Screening